Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies.

被引：0
|
作者：
Treon, SP
Mitsiades, CS
Mitsiades, NS
Young, G
Doss, DS
Schlossman, RL
Anderson, KC
机构：
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
426
引用
收藏
页码：99A / 99A
页数：1
相关论文
共 50 条
  • [1] Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
    Treon, SP
    Mitsiades, C
    Mitsiades, N
    Young, G
    Doss, D
    Schlossman, R
    Anderson, KC
    [J]. JOURNAL OF IMMUNOTHERAPY, 2001, 24 (03): : 263 - 271
  • [2] Ublituximab for the treatment of CD20 positive B-cell malignancies
    Babiker, Hani M.
    Glode, Ashley E.
    Cooke, Laurence S.
    Mahadevan, Daruka
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 407 - 412
  • [3] The future of CD20 monoclonal antibody therapy in B-cell malignancies
    Czuczman, Myron S.
    Gregory, Stephanie A.
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (06) : 983 - 994
  • [4] Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance
    Tomita, Akihiro
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2016, 56 (02) : 89 - 99
  • [5] The predictive significance of CD20 expression in B-cell lymphomas
    Prevodnik, Veronika Kloboves
    Lavrencak, Jaka
    Horvat, Mateja
    Novakovic, Barbara Jezersek
    [J]. DIAGNOSTIC PATHOLOGY, 2011, 6
  • [6] The predictive significance of CD20 expression in B-cell lymphomas
    Veronika Kloboves Prevodnik
    Jaka Lavrenčak
    Mateja Horvat
    Barbara Jezeršek Novakovič
    [J]. Diagnostic Pathology, 6
  • [7] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [8] Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance
    Henry, Carole
    Deschamps, Marina
    Rohrlich, Pierre-Simon
    Pallandre, Jean-Rene
    Remy-Martin, Jean-Paul
    Callanan, Mary
    Traverse-Glehen, Alexandra
    GrandClement, Camille
    Garnache-Ottou, Francine
    Gressin, Remy
    Deconinck, Eric
    Salles, Gilles
    Robinet, Eric
    Tiberghien, Pierre
    Borg, Christophe
    Ferrand, Christophe
    [J]. BLOOD, 2010, 115 (12) : 2420 - 2429
  • [9] CD19 and CD20 expression in chronic B-cell leukaemias.
    Ginaldi, L
    DeMartinis, M
    Matutes, E
    Farahat, N
    Morilla, R
    Catovsky, D
    [J]. BLOOD, 1997, 90 (10) : 4090 - 4090
  • [10] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Golay, J
    Lazzari, M
    Facchinetti, V
    Bernasconi, S
    Borleri, G
    Barbui, T
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2001, 98 (12) : 3383 - 3389
12345